AVBP: ArriVent BioPharma Inc

AVBP新闻

• 12:24 BTIG给ArriVent BioPharma股票首次评级为"买入"，看好其肿瘤治疗潜力
• 12:23 ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential
• 11:52 Truist证券给予ArriVent BioPharma买入评级，看好其肺癌药物前景
• 11:51 ArriVent BioPharma stock initiated with Buy rating at Truist on lung cancer drug
• 13:33 Clear Street上调ArriVent BioPharma目标价至47美元
• 13:31 ArriVent BioPharma stock price target raised to $47 from $32 at Clear Street
• 11:04 ArriVent BioPharma 32%的跌幅验证了InvestingPro的高估警告
• 11:04 ArriVent BioPharma’s 32% decline validates InvestingPro’s overvaluation warning
• 20:23 ArriVent BioPharma任命Brent Rice为首席商务官
• 12:05 ArriVent reports 16-month PFS for lung cancer drug firmonertinib
• 11:31 H.C. Wainwright raises ArriVent BioPharma stock price target to $42 on NSCLC drug potential
• 12:11 ArriVent Posts Wider Loss in Fiscal Q2
• 11:58 ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright
• 14:00 ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating
• 12:22 ArriVent expects topline data from lung cancer drug trial in early 2026
• 10:08 New Strong Sell Stocks for July 21st
• 11:24 ArriVent BioPharma stock rating resumed at Buy by Goldman Sachs
• 11:02 ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval
• 12:22 Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - BrightView Hldgs (NYSE:BV), ArriVent BioPharma (NASDAQ:AVBP)
• 20:13 ArriVent BioPharma announces $75 million public offering
• 11:40 ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright on strong NSCLC trial data
• 21:06 Clear Street initiates ArriVent BioPharma stock with Buy rating
• 17:51 Citi raises ArriVent BioPharma stock price target on lung cancer data
• 11:13 ArriVent reports 16-month progression-free survival for lung cancer drug